AstraZeneca failed to win FDA approval for its heart drug Brilinta, which the company -- facing a severe patent cliff -- has high hopes for. If approved, it could be a multibillion-dollar blockbuster. But the FDA wants to see more analyses of results from a major study. Continue reading AstraZeneca's Brilinta Fails to Win FDA Approval AstraZeneca's Brilinta Fails to Win FDA Approval originally appeared on DailyFinance on Fri, 17 Dec 2010 08:08:00. Filed Under: Company News , Health Care , Pfizer , Bristol-Myers Squibb , Sanofi Aventis , Astrazeneca , Stocks in the News Permalink | Tweet this! | Comments